ICGEB and the Indo-Canada research consortium for development of new anti-malarials against multiple targets in the parasite
Visiting Delhi for the signing of R&D collaborations, the Premier of Ontario, Canada, the Hon. Ms Kathleen Wynne announced the grant support for the Indo-Canada joint project "International malaria research consortium for the development of novel classes of antimalarials".
The Indo-Canada joint consortium under this project is funded from Government of Canada, Government of Ontario and by the Government of India; this consortium has been working on a number of drug targets to develop new chemical classes of drugs that are able to overcome drug resistance to provide improved global solutions for malaria therapy
Malaria is present in more than 100 countries. It is the single largest cause of death for children under five in sub-Saharan Africa, where it kills nearly one child every minute, or more than a 1,000 children every day.
The public and private partners in this collaboration include Toronto General Research Institute, University Health Network as the Canadian lead institute (Principal Investigator: Dr. Lakshmi P. Kotra), Therapure Biopharma, Nucro-Technics, CIDAVA Innovations, International Centre for Genetic Engineering and Biotechnology as the Indian lead institute (Principal Investigator: Dr. Asif Mohmmed), Lifecare Innovations-India and Birla Institute of Tech & Science-India.